Rodent models of chemotherapy-induced peripheral neuropathy

ILAR Journal

Volumn 54, Issue 3, 2014, Pages 273-281

  Höke, Ahmet ^a   Ray, Mitali ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Axon degeneration; Bortezomib; Chemotherapy; Cisplatin; Intraepidermal nerve fiber density; Paclitaxel; Peripheral neuropathy; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CISPLATIN; PACLITAXEL; PYRAZINE DERIVATIVE; VINCRISTINE;

ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MOUSE; NERVE DEGENERATION; NERVE FIBER; PERIPHERAL NEUROPATHY; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AXONS; BORONIC ACIDS; CISPLATIN; DISEASE MODELS, ANIMAL; MICE; NERVE DEGENERATION; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RATS; VINCRISTINE;

EID: 84897843931     PISSN: 10842020     EISSN: 19306180     Source Type: Journal    
DOI: 10.1093/ilar/ilt053     Document Type: Article

References (72)

1. Aley KO, Reichling DB, Levine JD. 1996. Vincristine hyperalgesia in the rat: A model of painful vincristine neuropathy in humans. Neuroscience 73:259-265.
2. Apfel SC, Arezzo JC, Lewis ME, Kessler JA. 1993. The use of insulin-like growth factor I in the prevention of vincristine neuropathy in mice. Ann N YAcad Sci 692:243-245.
3. Apfel SC, Arezzo JC, Lipson L, Kessler JA. 1992. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 31:76-80.
4. Armstrong JG, Dyke RW, Fouts PJ, Hawthorne JJ, Jansen CJ Jr, Peabody AM. 1967. Initial clinical experience with vinglycinate sulfate, a molecular modification of vinblastine. Cancer Res 27:221-227.
5. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. 2003. A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 24:797-805.
6. Black MM. 1987. Taxol interferes with the interaction of microtubuleassociated proteins with microtubules in cultured neurons. J Neurosci 7:3695-3702.
7. Boyle FM, Wheeler HR, Shenfield GM. 1996. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 279:410-415.
8. Bruna J, Udina E, Ale A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X. 2010. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223:599-608.
9. Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, Wozniak KM, Cavaletti G. 2010. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 17:380-391.
10. Carozzi V, Chiorazzi A, Canta A, Oggioni N, Gilardini A, Rodriguez-Menendez V, Avezza F, Crippa L, Ceresa C, Nicolini G, Bossi M, Cavaletti G. 2009. Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity. Eur J Cancer 45:656-665.
11. Cavaletti G, Tredici G, Braga M, Tazzari S. 1995. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133:64-72.
12. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. 1992. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 84:364-371.
13. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'incalci M, De Coster R. 2007. Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol 204:317-325.
14. Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG. 2001. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37:2457-2463.
15. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. 1994. Quantitative assessment of tactile allodynia in the rat paw. J NeurosciMeth 53:55-63.
16. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, Di Stefano PS. 1998. Physiological characterization of taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 43:46-55.
17. Coggeshall RE, Lekan HA. 1996. Methods for determining numbers of cells and synapses: A case for more uniform standards of review. J Compar Neurol 364:6-15.
18. Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC. 1997. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res 774:20-26.
19. D'amour FE, Smith DL. 1941. A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
20. De Leo JA, Rutkowski MD. 2000. Gender differences in rat neuropathic pain sensitivity is dependent on strain. Neurosci Lett 282:197-199. Drexler HC. 1997. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 94:855-860.
21. Drexler HC. 1997. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 94:855-860.
22. Grisold W, Cavaletti G, Windebank AJ. 2012. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-oncology 14:45-54.
23. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
24. Higuera ES, Luo ZD. 2004. A rat pain model of vincristine-induced neuropathy. Meth Mol Med 99:91-98.
25. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. 1976. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 36:3798-3802.
26. Hoke A. 2012. Animal models of peripheral neuropathies. Neurotherapeutics 9:262-269.
27. Holland NR, Stocks A, Hauer P, Cornblath DR, Griffin JW,Mc Arthur JC. 1997. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology 48:708-711.
28. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. 1995. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Comm 217:1070-1077.
29. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC. 2004. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Brit J Haemetol 127:165-172.
30. Jaggi AS, Singh N. 2012. Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats. Food Chem Toxicol 50:1295-1301.
31. Jones BJ, Roberts DJ. 1968. The quantiative measurement of motor incoordination in naive mice using an acelerating rotarod. J Pharmacy Pharmacol 20:302-304.
32. Kane RC, Farrell AT, Sridhara R, Pazdur R. 2006. United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12:2955-2960.
33. Kirchmair R, Tietz AB, Panagiotou E, Walter DH, Silver M, Yoon YS, Schratzberger P, Weber A, Kusano K, Weinberg DH, Ropper AH, Isner JM, Losordo DW. 2007. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: Taxol-and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther 15:69-75.
34. Krajewski K, Turansky C, Lewis R, Garbern J, Hinderer S, Kamholz J, Shy ME. 1999. Correlation between weakness and axonal loss in patients with CMT1A. Ann N YAcad Sci 883:490-492.
35. Leighton GE, Rodriguez RE, Hill RG, Hughes J. 1988. kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Brit J Pharmacol 93:553-560.
36. Mc Carthy BG, Hsieh ST, Stocks A, Hauer P, Macko C, Cornblath DR, Griffin JW, Mc Arthur JC. 1995. Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy. Neurology 45:1848-1855.
37. Melli G, Jack C, Lambrinos GL, Ringkamp M, Hoke A. 2006. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis 24:525-530.
38. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P, Cavaletti G. 2010. Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats. Eur J Pain 14:343-350.
39. Meregalli C, Ceresa C, Canta A, Carozzi VA, Chiorazzi A, Sala B, Oggioni N, Lanza M, Letari O, Ferrari F, Avezza F, Marmiroli P, Caselli G, Cavaletti G. 2012. CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res 5:151-167.
40. Mo M, Erdelyi I, Szigeti-Buck K, Benbow JH, Ehrlich BE. 2012. Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment. FASEB J 26:4696-4709.
41. Nakamura Y, Shimizu H, Nishijima C, Ueno M, Arakawa Y. 2001. Delayed functional recovery by vincristine after sciatic nerve crush injury: A mouse model of vincristine neurotoxicity. Neurosci Lett 304:5-8.
42. Necker R, Hellon RF. 1978. Noxious thermal input from the rat tail: modulation by descending inhibitory influences. Pain 4:231-242.
43. Nodera H, Spieker A, Sung M, Rutkove S. 2011. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. Neurosci Lett 505:223-227.
44. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. 2001. Vincristine-induced allodynia in the rat. Pain 93:69-76.
45. Oh SS, Hayes JM, Sims-Robinson C, Sullivan KA, Feldman EL. 2010. The effects of anesthesia on measures of nerve conduction velocity in male C57Bl6/J mice. Neurosci Lett 483:127-131.
46. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'connor OA, Soignet SL. 2002. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427.
47. Randall LO, Selitto JJ. 1957. A method for measurement of analgesic activity on inflamed tissue. Arch Int Thermodyn Ther 111:409-419.
48. Rebert CS, Pryor GT, Frick MS. 1984. Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J Appl Toxicol 4:330-338.
49. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. 1993. Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20:1-15. Roytta M, Raine CS. 1985. Taxol-induced neuropathy: Further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 14:157-175.
50. Roytta M, Raine CS. 1985. Taxol-induced neuropathy: Further ultrastructural studies of nerve fibre changes in situ. J Neurocytol 14:157-175.
51. Roytta M, Raine CS. 1986. Taxol-induced neuropathy: Chronic effects of local injection. J Neurocytol 15:483-496.
52. Ruiz-Medina J, Baulies A, Bura SA, Valverde O. 2013. Paclitaxel-induced neuropathic pain is age dependent and devolves on glial response. Eur J Pain 17:75-85.
53. Russell JW, Gill JS, Sorenson EJ, Schultz DA, Windebank AJ. 2001. Suramin-induced neuropathy in an animal model. J Neurol Sci 192:71-80.
54. Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Maeda T, Ozaki M, Kishioka S. 2009. Suppressive effect of imipramine on vincristineinduced mechanical allodynia in mice. Biol Pharm Bull 32:1231-1234.
55. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S. 1996. Apoptosis induction resulting from proteasome inhibition. Biochem J 317:385-388.
56. Smith SB, Crager SE, Mogil JS. 2004. Paclitaxel-induced neuropathic hypersensitivity in mice: Responses in 10 inbred mouse strains. Life Sci 74:2593-2604.
57. Sullivan KA, Lentz SI, Roberts JL Jr, Feldman EL. 2008. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 9:3-13.
58. Sweitzer SM, Pahl JL, De Leo JA. 2006. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett 400:258-261.
59. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. 2010. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 6:15.
60. Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA,Windebank AJ. 2013. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PloS One 8:e54161.
61. Thiagarajan VR, Shanmugam P, Krishnan UM, Muthuraman A, Singh N. 2013. Antinociceptive effect of Butea monosperma on vincristineinduced neuropathic pain model in rats. Toxicol Industrial health 29:3-13.
62. Tomiwa K, Nolan C, Cavanagh JB. 1986. The effects of cisplatin on rat spinal ganglia: A study by light and electron microscopy and by morphometry. Acta Neuropathol 69:295-308.
63. Trevisan G, Materazzi S, Fusi C, Altomare A, Aldini G, Lodovici M, Patacchini R, Geppetti P, Nassini R. 2013. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res 73:3120-3131.
64. Uceyler N, Kobsar I, Biko L, Ulzheimer J, Levinson SR, Martini R, Sommer C. 2006. Heterozygous P0 deficiency protects mice from vincristine-induced polyneuropathy. J Neurosci Res 84:37-46.
65. Verdu E, Vilches JJ, Rodriguez FJ, Ceballos D, Valero A, Navarro X. 1999. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 22:329-340.
66. Wala EP, Crooks PA, Mc Intosh JM, Holtman JR Jr. 2012 Novel small molecule alpha9alpha10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats. Anesthesia Analgesia 115:713-720.
67. Wang MS, Davis AA, Culver DG, Glass JD. 2002. WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 52: 442-447
68. Wang MS, Davis AA, Culver DG,Wang Q, Powers JC, Glass JD. 2004. Calpain inhibition protects against taxol-induced sensory neuropathy. Brain 127:671-679.
69. Windebank AJ, Grisold W. 2008. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27-46.
70. Xia RH, Yosef N, Ubogu EE. 2010. Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: Technical aspects and normative data. Muscle Nerve 41:850-856.
71. Zhang J,Wu P, Hu Y. 2013. Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem 20:2537-2551.
72. Zheng H, Xiao WH, Bennett GJ. 2012. Mitotoxicity and bortezomibinduced chronic painful peripheral neuropathy. Exp Neurol 238: 225-234.